News | February 24, 2026
Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
Under the deal, Quiver will receive an undisclosed advance payment and research support
Under the deal, Quiver will receive an undisclosed advance payment and research support
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Subscribe To Our Newsletter & Stay Updated
